论文部分内容阅读
目的探讨CA125、CA199、CEA联合检测在子宫内膜癌临床诊断中的应用价值。方法选择子宫内膜癌组115例、健康对照组90例,采用自动荧光磁微粒酶免分析法检测血清中CA199、CA125的含量,采用光激化学发光法检测血清中CEA的含量。结果子宫内膜癌组血清中CA125、CA199、CEA的水平较高于对照组(P<0.05);CA125、CA199、CEA联合检测对早期子宫内膜癌临床诊断的阳性率较单独检测高,差异有统计学意义(P<0.05)。结论 CA125、CA199、CEA联合检测在提高子宫内膜癌临床早期诊断的阳性率方面具有重要的价值。
Objective To investigate the clinical value of combined detection of CA125, CA199 and CEA in the clinical diagnosis of endometrial carcinoma. Methods One hundred and fifteen patients with endometrial carcinoma and 90 healthy controls were enrolled in this study. Serum levels of CA199 and CA125 were detected by automated fluorescent magnetic particle enzyme immunoassay. The levels of CEA in serum were determined by chemiluminescence assay. Results The serum levels of CA125, CA199 and CEA in endometrial carcinoma group were higher than those in control group (P <0.05). The positive rates of CA125, CA199 and CEA in the clinical diagnosis of early endometrial carcinoma were higher than those in the endometrial carcinoma alone group, There was statistical significance (P <0.05). Conclusion The combined detection of CA125, CA199 and CEA is of great value in improving the positive rate of early clinical diagnosis of endometrial cancer.